Clinical trial
A Phase III Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4, and 12 Months (V419-007-03)
NCT01341639 is registered in ClinicalTrials.gov with MCM Vaccines B.V. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4, and 12 Months (V419-007-03)
- Lead sponsor
- MCM Vaccines B.V.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- May 26, 2011
- Completion date
- March 13, 2013
- Enrollment
- 1,250 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.